Acrux signs second distribution agreement with CSL

By Melissa Trudinger
Tuesday, 30 November, 2004

Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.

The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.

Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.

Related News

Oxytocin analogue treats chronic abdominal pain

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd